Metrics to compare | ALNFL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALNFLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.2x | −3.0x | −0.4x | |
PEG Ratio | 0.13 | −0.05 | 0.00 | |
Price / Book | 34.8x | 1.4x | 2.6x | |
Price / LTM Sales | 56,620.7x | 14.5x | 3.0x | |
Upside (Analyst Target) | - | 145.7% | 56.9% | |
Fair Value Upside | Unlock | −2.5% | 9.2% | Unlock |
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.